Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

被引:0
作者
Geerts, Julie F. M. [1 ,2 ]
van der Zijden, Charlene J. [2 ]
van der Sluis, Pieter C. [2 ]
Spaander, Manon C. W. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Rosman, Camiel [4 ]
van Laarhoven, Hanneke W. M. [5 ,6 ]
Verhoeven, Rob H. A. [5 ,6 ,7 ]
Wijnhoven, Bas P. L. [2 ]
Lagarde, Sjoerd M. [2 ]
Mostert, Bianca [8 ]
机构
[1] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
[2] Erasmus MC, Dept Surg, Canc Inst, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[4] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC Locat, NL-1081 HV Amsterdam, Netherlands
[6] Canc Ctr Amsterdam, Canc Treatment & Qual Life, NL-1105 AZ Amsterdam, Netherlands
[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 LC Utrecht, Netherlands
[8] Erasmus MC, Dept Med Oncol, Canc Inst, NL-3015 GD Rotterdam, Netherlands
关键词
esophageal cancer; gastro-esophageal cancer; gastric cancer; neoadjuvant chemotherapy; esophagectomy; STAGING LAPAROSCOPY; ADENOCARCINOMA; SURVIVAL; 5-FLUOROURACIL; CAPECITABINE; OXALIPLATIN;
D O I
10.3390/cancers16071291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015-2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77-1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09-1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08-1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05-2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
引用
收藏
页数:12
相关论文
共 37 条
  • [1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [2] Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
    Al-Batran, Salah-Eddin
    Homann, Nils
    Schmalenberg, Harald
    Knopp, Hans-Georg
    Georg
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] [Anonymous], 2009, TNM classification of malignant tumors, V7th edn
  • [4] [Anonymous], Protocol for the examination of specimens from patients with invasive carcinoma of the breast
  • [5] [Anonymous], Integraal Kankercentrum Nederland Slokdarm-en Maagkanker in Nederland
  • [6] Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit
    Busweiler, L. A. D.
    Wijnhoven, B. P. L.
    Henegouwen, M. I. van Berge
    Henneman, D.
    van Grieken, N. C. T.
    Wouters, M. W. J. M.
    van Hillegersberg, R.
    van Sandick, J. W.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 (13) : 1855 - 1863
  • [7] Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
    Cassidy, J.
    Saltz, L.
    Twelves, C.
    Van Cutsem, E.
    Hoff, P.
    Kang, Y.
    Saini, J. P.
    Gilberg, F.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (12) : 2604 - 2609
  • [8] The Current Role of Staging Laparoscopy in Oesophagogastric Cancer
    Convie, L.
    Thompson, R. J.
    Kennedy, R.
    Clements, W. D. B.
    Carey, P. D.
    Kennedy, J. A.
    [J]. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2015, 97 (02) : 146 - 150
  • [9] Capecitabine and oxaliplatin for advanced esophagogastric cancer
    Cunningham, David
    Starling, Naureen
    Rao, Sheela
    Iveson, Timothy
    Nicolson, Marianne
    Coxon, Fareeda
    Middleton, Gary
    Daniel, Francis
    Oates, Jacqueline
    Norman, Andrew Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) : 36 - 46
  • [10] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, David
    Allum, William H.
    Stenning, Sally P.
    Thompson, Jeremy N.
    Van de Velde, Cornelis J. H.
    Nicolson, Marianne
    Scarffe, J. Howard
    Lofts, Fiona J.
    Falk, Stephen J.
    Iveson, Timothy J.
    Smith, David B.
    Langley, Ruth E.
    Verma, Monica
    Weeden, Simon
    Chua, Yu Jo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20